This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Abclon Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Young-Ha Lee: Innovator in Cancer Therapy
Introduction
Young-Ha Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer therapy through his innovative research and development of antibodies targeting HER2.
Latest Patents
Young-Ha Lee holds a patent for an antibody specifically binding to HER2, which is crucial in the prevention and treatment of cancers. This invention focuses on HER2 (Human Epidermal Growth Factor Receptor 2) antibodies that bind specifically to HER2 over-expressed in cancer cells, particularly in breast and stomach cancers. The unique CDR sequences of these antibodies exhibit low similarity to those of publicly known HER2 antibodies, highlighting their distinctiveness. The antibodies, when used in combination with trastuzumab, demonstrate significantly enhanced cytotoxicity, making them highly effective in cancer therapy.
Career Highlights
Young-Ha Lee is associated with Abclon Inc., where he continues to advance his research in antibody development. His work has the potential to revolutionize cancer treatment, particularly for patients with HER2-positive cancers.
Collaborations
Young-Ha Lee collaborates with notable colleagues, including Jong-Seo Lee and Kyu-Tae Kim, to further enhance the efficacy of cancer therapies.
Conclusion
Young-Ha Lee's innovative work in developing HER2-targeting antibodies represents a significant advancement in cancer treatment. His contributions are paving the way for more effective therapies for patients battling cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile